CAMBRIDGE, Mass., Jan. 29, 2014 /PRNewswire/ -- Metamark Genetics, Inc., a leader in the discovery of molecular and prognostic tests for cancer, today announced the appointment of Jonathan Lieber as Senior Vice President and Chief Financial Officer. He will report to Metamark President and Chief Executive Officer Shawn M. Marcell and join the company's executive team.<br /><br />The appointment of Mr. Lieber is the most recent expansion of the executive team as Metamark prepares for the launch this year of ProMark™, a novel prognostic test for the management of prostate cancer.<br /><br />"Jon possesses exceptional leadership, extensive biotech financial experience, knowledge of financial markets, and a record of success," said Mr. Marcell. "His combination of public- and private-company operating experience together with his years in investment banking fits perfectly with Metamark's strategic plans."<br /><br />Mr. Lieber commented, "I join Metamark with the excitement of knowing the company is realizing its ambition of providing a wide array of specialty-testing services that will make a difference for cancer patients. "ProMark™, which promises to be a true advance in aiding decision-making in the treatment of prostate cancer, shows the power of the Metamark discovery platform to deliver novel prognostic and diagnostic tools for cancer care. I am excited about the opportunity created by the integration of this platform with the specialty, urology, laboratory services business and commercial organization recently acquired by Metamark."<br /><br />Mr. Lieber brings to Metamark more than a decade of experience as the chief financial officer of emerging life-sciences companies including, Repligen Corporation, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. He led all capital-raising activities, including a $110-million initial public offering for Altus.  Prior to serving as a CFO, Mr. Lieber worked as an investment banker for 10 years, originating and executing numerous corporate financings and mergers and acquisitions. He received a B.S. in business administration and finance from Boston University and an M.B.A. from the New York University Stern School of Business. <br /><br />About ProMark™<br /><br />ProMark™ is a biopsy-based prostate-cancer prognostic test. A large, blinded, clinical-validation study of ProMark™ met its primary endpoint, demonstrating that ProMark™, evaluated in standard, formalin-fixed, paraffin-embedded prostate tissue, can differentiate indolent from aggressive disease. The study followed three prior studies totaling over 1,250 patient cases, which were conducted by Metamark using its proprietary, protein-based, multiplex-imaging platform. Metamark plans to make ProMark™ available to pathologists, urologists, and their patients in early 2014.  <br /><br />About Metamark<br /><br />Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.